10x Genomics (TXG) Operating Leases (2020 - 2025)
Historic Operating Leases for 10x Genomics (TXG) over the last 6 years, with Q4 2025 value amounting to $84.4 million.
- 10x Genomics' Operating Leases rose 1504.77% to $84.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $84.4 million, marking a year-over-year increase of 1504.77%. This contributed to the annual value of $84.4 million for FY2025, which is 1504.77% up from last year.
- As of Q4 2025, 10x Genomics' Operating Leases stood at $84.4 million, which was up 1504.77% from $87.0 million recorded in Q3 2025.
- In the past 5 years, 10x Genomics' Operating Leases ranged from a high of $102.0 million in Q1 2023 and a low of $70.8 million during Q2 2021
- In the last 5 years, 10x Genomics' Operating Leases had a median value of $86.4 million in 2022 and averaged $87.3 million.
- Its Operating Leases has fluctuated over the past 5 years, first surged by 3981.11% in 2022, then tumbled by 1312.92% in 2025.
- Quarter analysis of 5 years shows 10x Genomics' Operating Leases stood at $76.8 million in 2021, then grew by 12.09% to $86.1 million in 2022, then dropped by 2.66% to $83.8 million in 2023, then decreased by 12.55% to $73.3 million in 2024, then grew by 15.05% to $84.4 million in 2025.
- Its Operating Leases was $84.4 million in Q4 2025, compared to $87.0 million in Q3 2025 and $86.7 million in Q2 2025.